Skip to main content

Tali M. Tuchin

Member

[email protected]

+1.858.314.1558

Share:

Tali has over 20 years of extensive experience managing a wide range of complex transactions for life science and biotechnology companies. Her clients span the biotechnology, pharmaceuticals, diagnostics, medical device, healthcare, and energy sectors, ranging from start-ups to publicly traded companies with approved drugs and devices. She negotiates deals that advance her clients' commercial interests while mitigating risk.

Her clients work on cutting-edge technologies, including RNA and mRNA therapeutics, antibody and protein therapeutics (including ADCs and CARs), vaccines and vaccine delivery devices, reproductive healthcare products, oncology platforms, drug discovery platforms leveraging AI, pain relief innovations, brain health solutions, orphan drugs, research reagents, and in vitro and clinical diagnostics. Tali helps clients establish and manage alliances to identify, develop, and commercialize drug candidates, diagnostics, and innovative technologies.

She provides strategic counsel on collaborations, strategic alliances, patent licenses and assignments, research and development agreements, and joint development agreements. Her focus is on keeping critical deals on track, working efficiently, and maximizing business value.

Drawing on her prior experience as in-house corporate counsel for a large, publicly traded biotech company, Tali serves as a trusted business advisor. She understands and accommodates the complexities that can influence intricate deals. Companies rely on her comprehensive transactional expertise and insightful advice to manage investor expectations, control legal costs, address the needs of diverse internal stakeholders, and navigate negotiation challenges. Her clients benefit from her extensive experience and innovative problem-solving approach.

In addition to high-stakes transactions, Tali also handles agreements for day-to-day business operations. These include material transfer and option agreements, clinical supply and research agreements, clinical trial agreements, manufacturing and supply agreements (CDMOs), and service agreements (CROs). She also supports clients by managing and reviewing high-volume routine work, such as confidentiality agreements, customer agreements, and terms and conditions.

 

Experience

  • Arcturus Therapeutics (Nasdaq:ARCT), a leading clinical-stage messenger RNA medicines company, in connection with its partnership agreement with CSL Seqirus for a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines
  • Daré Bioscience in connection with its partnership agreement with Oragonon a global women’s healthcare company
  • Caladrius Biosciences (Nasdaq:CLBS), a biopharmaceutical company engaged in regenerative medicine and stem cell research, in connection with its merger with Cend Therapeutics – the combined company will operate under the name Lisata Therapeutics (Nasdaq:LSTA)
  • Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a biotherapeutics company, in a license agreement with Baylor BioSciences, a life sciences company
  • Immusoft Corporation in its first Big Pharma collaboration in a deal with Takeda valued at $900M
  • Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots, in connection with its sale to Abbott (NYSE:ABT)
  • BlinkBio in out-licensing its patent rights to OS Therapies, a late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors
  • BlinkBio in out-licensing its patent rights to ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors
  • Nuvve Corporation (Nasdaq:NVVE) with respect to its electric school bus and fleet vehicle  electrification-as-a-service joint venture with Stonepeak Infrastructure Partners providing up to $750M in financing
Read less

viewpoints

Amid a tough equity market and an ebb in investment in the biotech sector, early- or growth-stage companies focused on drug discovery and development may want to spend some time exploring strategic partnerships with other businesses at the 2023 BIO International Convention.

Read more
Read less

News & Press

Press Release Thumbnail Mintz

187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.

Press Release Thumbnail Mintz

Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.

Press Release Thumbnail Mintz

Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.

Mintz is pleased to announce Tali M. Tuchin has been named a finalist for the 2018 Athena Pinnacle Awards. Ms. Tuchin, Special Counsel in the firm’s San Diego office, has been recognized in Athena’s “Individual in Services” category.
Read less

Events & Speaking

Panelist
Feb
7
2019

Living Heart Healthy & Stress-Free

Willis Towers Watson, San Diego, CA

Speaker
Jun
2
2015
Read less

Recognition & Awards

  • Recognized by Athena - Pinnacle Award Finalist - Individual in Services (2018)

  • Best Lawyers in America: IT/Outsourcing Law (2023 – 2025)

Read less

Involvement

  • Member, Athena Forum for Executive Women (FEW) group (2010-present)
  • Member, Lawyers Club of San Diego
  • Volunteer, Women in Bio, San Diego Chapter (2022-present)
Read less